News & Updates
Filter by Specialty:
VELO supports liquid biopsy-guided anti-EGFR rechallenge therapy in mCRC
In the phase II VELO trial, third-line (3L) treatment with the anti-EGFR* monoclonal antibody (mAb) panitumumab and standard of care (SoC) improved progression-free survival (PFS) in patients with refractory RAS wild-type metastatic colorectal cancer (WT mCRC).
VELO supports liquid biopsy-guided anti-EGFR rechallenge therapy in mCRC
12 Sep 2023
Pancreatic cancer often overlooked, diagnosed late
Pancreatic cancer, recognized as a silent yet potent malignancy, stands among the most lethal forms of cancer. Although ranking as the twelfth most prevalent cancer diagnosed globally, it claims the seventh highest fatality rate, with a disappointing 5 to 10 percent 5-year survival rate. [Available at https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis Accessed on 30 August 2023] According to the Global Cancer Observatory 2020 (Globocan) report by the WHO, Malaysia had 1,089 new cases of pancreatic cancer, resulting in 1,066 fatalities. Notably, the incidence was calculated at approximately two individuals per 100,000.
Pancreatic cancer often overlooked, diagnosed late
12 Sep 2023
Triple G agonist shows therapeutic potential in obesity
Treatment with retatrutide, the novel agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, leads to marked reductions in body weight in individuals with obesity, as shown in the results of a phase II trial.
Triple G agonist shows therapeutic potential in obesity
11 Sep 2023
HEART-FID confirms IV iron safety for HF but falls short in efficacy
The HEART-FID trial narrowly missed its primary endpoint, showing modest improvement in all-cause mortality, heart failure hospitalizations (hHF), and exercise function with ferric carboxymaltose (FCM) in HFrEF* patients with iron deficiency (ID).
